Exploiting orthology and de novo transcriptome assembly to refine target sequence information.

Comparative genomics Orthology RNA-Seq Sequence refinement de novo transcriptome assembly

Journal

BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628

Informations de publication

Date de publication:
23 05 2019
Historique:
received: 07 11 2018
accepted: 08 05 2019
entrez: 25 5 2019
pubmed: 28 5 2019
medline: 31 12 2019
Statut: epublish

Résumé

The ability to generate recombinant drug target proteins is important for drug discovery research as it facilitates the investigation of drug-target-interactions in vitro. To accomplish this, the target's exact protein sequence is required. Public databases, such as Ensembl, UniProt and RefSeq, are extensive protein and nucleotide sequence repositories. However, many sequences for non-human organisms are predicted by computational pipelines and may thus be incomplete or incorrect. This could lead to misinterpreted experimental outcomes due to gaps or errors in orthologous drug target sequences. Transcriptome analysis by RNA-Seq has been established as a standard method for gene expression analysis. Apart from this common application, paired-end RNA-Seq data can also be used to obtain full coverage cDNA sequences via de novo transcriptome assembly. To assess whether de novo transcriptome assemblies can be used to determine a protein's sequence by searching the assembly for a known orthologous sequence, we generated 3 × 6 = 18 tissue specific assemblies (three organs: brain, kidney and liver; six species: human, mouse, rat, dog, pig and cynomolgus monkey). These assemblies and the manually curated human protein sequences from UniProtKB/Swiss-Prot were used in a reciprocal BLAST search to identify best matching hits. We automated and generalised our approach and present the a&o-tool, a workflow which exploits de novo assemblies of paired-end RNA-Seq data and orthology information for target sequence validation and refinement across related species. Furthermore, the a&o-tool extracts best hits' sequences from a reciprocal BLAST search, translates them into protein sequences, computes a multiple sequence alignment and quantifies the refinement. For the three human assemblies we observed a hit rate greater than 60% with 100% sequence coverage and identity. For assemblies from the other species we observed similar hit rates and coverage with highest identities for cynomolgus monkey. In summary, we show how to refine protein sequences using RNA-Seq data and sequence information from closely related species. With the a&o-tool we provide a fully automated pipeline to perform refinement including cDNA translation and multiple sequence alignment for visual inspection. The major prerequisite for applying the a&o-tool is high quality sequencing data.

Sections du résumé

BACKGROUND
The ability to generate recombinant drug target proteins is important for drug discovery research as it facilitates the investigation of drug-target-interactions in vitro. To accomplish this, the target's exact protein sequence is required. Public databases, such as Ensembl, UniProt and RefSeq, are extensive protein and nucleotide sequence repositories. However, many sequences for non-human organisms are predicted by computational pipelines and may thus be incomplete or incorrect. This could lead to misinterpreted experimental outcomes due to gaps or errors in orthologous drug target sequences. Transcriptome analysis by RNA-Seq has been established as a standard method for gene expression analysis. Apart from this common application, paired-end RNA-Seq data can also be used to obtain full coverage cDNA sequences via de novo transcriptome assembly.
METHODS
To assess whether de novo transcriptome assemblies can be used to determine a protein's sequence by searching the assembly for a known orthologous sequence, we generated 3 × 6 = 18 tissue specific assemblies (three organs: brain, kidney and liver; six species: human, mouse, rat, dog, pig and cynomolgus monkey). These assemblies and the manually curated human protein sequences from UniProtKB/Swiss-Prot were used in a reciprocal BLAST search to identify best matching hits. We automated and generalised our approach and present the a&o-tool, a workflow which exploits de novo assemblies of paired-end RNA-Seq data and orthology information for target sequence validation and refinement across related species. Furthermore, the a&o-tool extracts best hits' sequences from a reciprocal BLAST search, translates them into protein sequences, computes a multiple sequence alignment and quantifies the refinement.
RESULTS
For the three human assemblies we observed a hit rate greater than 60% with 100% sequence coverage and identity. For assemblies from the other species we observed similar hit rates and coverage with highest identities for cynomolgus monkey.
CONCLUSIONS
In summary, we show how to refine protein sequences using RNA-Seq data and sequence information from closely related species. With the a&o-tool we provide a fully automated pipeline to perform refinement including cDNA translation and multiple sequence alignment for visual inspection. The major prerequisite for applying the a&o-tool is high quality sequencing data.

Identifiants

pubmed: 31122257
doi: 10.1186/s12920-019-0524-5
pii: 10.1186/s12920-019-0524-5
pmc: PMC6533699
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

69

Références

Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Genome Res. 2016 Aug;26(8):1134-44
pubmed: 27252236
Genome Res. 2015 Jun;25(6):918-25
pubmed: 25883319
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
IEEE Trans Vis Comput Graph. 2014 Dec;20(12):1983-92
pubmed: 26356912
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
PLoS Comput Biol. 2010 Mar 26;6(3):e1000703
pubmed: 20361041
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Sci Data. 2017 Dec 12;4:170185
pubmed: 29231921
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Nat Biotechnol. 2010 Dec;28(12):1248-50
pubmed: 21139605
Aging Cell. 2015 Jun;14(3):352-65
pubmed: 25677554
Nucleic Acids Res. 2014 Jan;42(Database issue):D60-7
pubmed: 24163100
Gigascience. 2018 Aug 1;7(8):
pubmed: 30052957
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Nat Biotechnol. 2017 Apr 11;35(4):316-319
pubmed: 28398311
Nat Protoc. 2013 Aug;8(8):1494-512
pubmed: 23845962
PLoS Comput Biol. 2016 Feb 19;12(2):e1004772
pubmed: 26894997
BMC Bioinformatics. 2008 Jun 13;9:278
pubmed: 18554390
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147

Auteurs

Julia F Söllner (JF)

Computational Biology & Genomics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.
Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Germán Leparc (G)

Transl. Medicine + Clin. Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Matthias Zwick (M)

Computational Biology & Genomics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Tanja Schönberger (T)

Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Tobias Hildebrandt (T)

Computational Biology & Genomics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany.

Kay Nieselt (K)

Integrative Transcriptomics, Center for Bioinformatics, University of Tübingen, Sand 14, 72076, Tübingen, Germany.

Eric Simon (E)

Computational Biology & Genomics, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany. eric.simon@boehringer-ingelheim.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH